Personalized Cancer Vaccine Boosts Recurrence-Free Survival in Melanoma
ORLANDO — Adding a personalized cancer vaccine to anti-PD-1 immunotherapy for resectable melanoma led to a 44% improvement in recurrence-free survival (RFS) versus immunotherapy alone, according to a study reported here. Patients who received the mRNA vaccine, derived from their own tumor, had an 18-month RFS of 78.6% as compared with 62.2% for patients who […]